Concepedia

Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study

Charles Kyung Min Lee, Shufeng Li, Duy Tran, Gefei Alex Zhu, Jinah Kim, Bernice Y. Kwong, Anne Lynn S. Chang

Journal of the American Academy of Dermatology · 2018 · 117 citations · 15 references

DOIFull text

Open access

Concepts

References

15

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text

, , +17

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

, , +17

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid, Caroline Robert, Adil Daud et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

, , +17

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 <sup>+</sup> T lymphocytes are prognostic factors of human ovarian cancer

Junzo Hamanishi, Masaki Mandai, Masashi Iwasaki et al. · Proceedings of the National Academy of Sciences · 2007 · 1.4K citations · Full text

, , +17

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

Camille Hua, Lise Boussemart, Christine Mateus et al. · JAMA Dermatology · 2015 · 650 citations

, , +17